IPHA stock forecast, quote, news & analysis
Innate Pharma SA is a clinical-stage biotechnology company... Show more
Why Innate Pharma S.A. (IPHA) Is Down -24% in the Last 30 Days
Key Takeaways
- IPHA stock declined approximately -24% over the past 30 days amid biotech sector volatility and company-specific financial pressures.
- Over the past quarter, the stock fell around -30%, reflecting broader declines from early 2026 highs near $1.80 to current levels around $1.30.
- Recent full-year 2025 earnings revealed declining revenue and a reduced cash runway to Q3 2026, contributing to negative sentiment.
- Positive analyst coverage from BTIG with a Buy rating and $8 target provided brief support, but failed to reverse the downtrend.
- Ongoing clinical trials and partnerships with AstraZeneca and Sanofi remain key, but funding concerns dominate market trends.
- Stock exhibited high volatility with sharp drops to 52-week lows near $1.17 before partial recovery.
Innate Pharma S.A. (IPHA) Company Overview and Market Position
Innate Pharma S.A. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. Its core business model centers on advancing a pipeline of innovative antibodies and NK cell engagers targeting tumor microenvironments. Key assets include Lacutamab in Phase II/III for cutaneous T-cell lymphoma, Monalizumab in Phase III for solid tumors partnered with AZN, and early-stage programs like IPH4502. Operating in the competitive oncology biotech sector, Innate Pharma collaborates with major players like AstraZeneca and Sanofi, providing milestone-based revenue but exposing it to clinical and financing risks. These fundamentals explain recent stock price behavior, as investors weigh pipeline potential against cash burn and trial outcomes in a challenging biotech funding environment.
Innate Pharma S.A. (IPHA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, IPHA stock has dropped roughly -24%, trading from around $1.71 on February 27 to $1.30 as of the latest close. The movement was volatile and trend-driven downward, hitting a 52-week low of $1.17 on March 20 before a partial rebound with spikes to $1.37 on March 23. Volume surged on down days, indicating selling pressure.
For the past quarter, the stock declined approximately -30%, starting near $1.82 in early January and steadily eroding amid range-bound trading between $1.50-$1.80 before accelerating lower in March. The decline was steady with intermittent volatility tied to news events, underperforming broader market trends in biotech.
What Drove IPHA Stock Price in the Last 30 Days
The primary catalyst for IPHA's 30-day decline was the March 25 release of full-year 2025 financial results, showing revenue of €9 million (down 55% YoY), a €49.2 million net loss, and cash of €44.8 million—sufficient only until Q3 2026. This raised going-concern doubts and funding needs for Lacutamab's Phase 3 trial, pressuring the stock despite cost cuts and pipeline updates. Shares dipped post-earnings before BTIG initiated Buy coverage on March 12 with an $8 target, citing 2026 catalysts like Monalizumab data, sparking a 17% jump on March 23. However, biotech sector weakness and negative shareholders' equity overwhelmed positives, driving the net downtrend. Macro factors like tight financing for small-cap biotechs amplified the pressure.
What Drove IPHA Stock Performance Over the Last Quarter
The quarterly downturn stemmed from sustained biotech market headwinds, including elevated interest rates curbing risk appetite and investor rotation from speculative names. Innate Pharma's revenue drop and cash burn highlighted vulnerabilities, with shares sliding from $1.80 highs amid low volume range-bound trading. Institutional behavior showed caution, as negative equity and discontinued programs like IPH6501 eroded confidence. Sector developments, such as oncology trial delays peers, compounded issues, though partnerships provided milestones. Cumulative impact favored bears, with financing risks proving strongest.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from hundreds available, which analyze and trade thousands of tickers across various markets. These curated bots are selected based on recent performance metrics like win rate, profit factor, and drawdown, varying by strategy—such as trend-following, mean reversion, or momentum—and timeframes from intraday to long-term. Users gain insights into real-time bot activity, backtested results, and live trading stats to identify relevant tools for stocks like IPHA. Explore the page to discover bots tailored to biotech volatility or sector trends and enhance your stock analysis today.
IPHA Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming milestones like IPH5201 interim data at AACR 2026, PACIFIC-9 Phase 3 readout in H2 2026, and Lacutamab Phase 3 initiation (H2 2026, funding-dependent). Progress in IPH4502 Phase 1, non-dilutive financing deals, and Q1 2026 earnings will shape sentiment. Broader macro conditions, including interest rates and biotech M&A activity, alongside regulatory updates from FDA on key assets, pose risks and catalysts. Streamlining efforts and ATM program usage could impact dilution risks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
IPHA in upward trend: price rose above 50-day moving average on April 14, 2026
IPHA moved above its 50-day moving average on April 14, 2026 date and that indicates a change from a downward trend to an upward trend. In of 68 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on April 08, 2026. You may want to consider a long position or call options on IPHA as a result. In of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IPHA just turned positive on April 01, 2026. Looking at past instances where IPHA's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for IPHA crossed bullishly above the 50-day moving average on April 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where IPHA advanced for three days, in of 210 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 120 cases where IPHA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for IPHA moved out of overbought territory on April 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 16 similar instances where the indicator moved out of overbought territory. In of the 16 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
IPHA broke above its upper Bollinger Band on April 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IPHA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.080) is normal, around the industry mean (26.613). P/E Ratio (0.000) is within average values for comparable stocks, (45.982). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (44.053) is also within normal values, averaging (325.079).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IPHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment
Industry Biotechnology